Intracranial Response to Selpercatinib After Pralsetinib-Induced Disease Progression in Rearranged During Transfection Fusion-Positive Non-Small-Cell Lung Cancer: Case Report
RET fusion-positive NSCLC accounts for 1% to 2% of lung carcinoma cases. Although two Food and Drug Administration–approved selective RET inhibitors, pralsetinib, and selpercatinib, have revealed efficacy in managing RET fusion-positive NSCLC, this case series is unique in its focus on the intracran...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | JTO Clinical and Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666364324001000 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850169397603205120 |
|---|---|
| author | Illaa Smesseim, MD Tijmen van der Wel, MD Sushil K. Badrising, MD, PhD |
| author_facet | Illaa Smesseim, MD Tijmen van der Wel, MD Sushil K. Badrising, MD, PhD |
| author_sort | Illaa Smesseim, MD |
| collection | DOAJ |
| description | RET fusion-positive NSCLC accounts for 1% to 2% of lung carcinoma cases. Although two Food and Drug Administration–approved selective RET inhibitors, pralsetinib, and selpercatinib, have revealed efficacy in managing RET fusion-positive NSCLC, this case series is unique in its focus on the intracranial response to selpercatinib after disease progression during pralsetinib treatment. This report contributes to the literature by providing evidence of selpercatinib’s potential as a treatment option in such refractory cases. The patients described in both cases were diagnosed with metastatic RET fusion-positive NSCLC and developed intracranial metastases during pralsetinib treatment. After switching to selpercatinib, both exhibited significant intracranial responses. The first patient reported a reduction in brain metastasis size and maintained a response for over 1.5 years. The second patient also responded intracranially to selpercatinib but unfortunately passed away 8 months later owing to pulmonary hemorrhage, possibly linked to prior radiation treatment. These cases highlight the potential efficacy of selpercatinib in treating intracranial metastases in RET fusion-positive patients with NSCLC after pralsetinib-refractory progression. The key takeaway is that selpercatinib may offer a viable treatment option in such scenarios, although more extensive studies are needed to determine its role as a monotherapy or in combination with other treatments. |
| format | Article |
| id | doaj-art-b85dc2fa0d424aee88a8beffee93b8fd |
| institution | OA Journals |
| issn | 2666-3643 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JTO Clinical and Research Reports |
| spelling | doaj-art-b85dc2fa0d424aee88a8beffee93b8fd2025-08-20T02:20:44ZengElsevierJTO Clinical and Research Reports2666-36432024-12-0151210073010.1016/j.jtocrr.2024.100730Intracranial Response to Selpercatinib After Pralsetinib-Induced Disease Progression in Rearranged During Transfection Fusion-Positive Non-Small-Cell Lung Cancer: Case ReportIllaa Smesseim, MD0Tijmen van der Wel, MD1Sushil K. Badrising, MD, PhD2Corresponding author. Address for correspondence: Illaa Smesseim, MD, Department of Thoracic Oncology, Netherlands Cancer Institute, Plesmanlaan 121 A 1066 CX, Amsterdam, The Netherlands.; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The NetherlandsDepartment of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The NetherlandsDepartment of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The NetherlandsRET fusion-positive NSCLC accounts for 1% to 2% of lung carcinoma cases. Although two Food and Drug Administration–approved selective RET inhibitors, pralsetinib, and selpercatinib, have revealed efficacy in managing RET fusion-positive NSCLC, this case series is unique in its focus on the intracranial response to selpercatinib after disease progression during pralsetinib treatment. This report contributes to the literature by providing evidence of selpercatinib’s potential as a treatment option in such refractory cases. The patients described in both cases were diagnosed with metastatic RET fusion-positive NSCLC and developed intracranial metastases during pralsetinib treatment. After switching to selpercatinib, both exhibited significant intracranial responses. The first patient reported a reduction in brain metastasis size and maintained a response for over 1.5 years. The second patient also responded intracranially to selpercatinib but unfortunately passed away 8 months later owing to pulmonary hemorrhage, possibly linked to prior radiation treatment. These cases highlight the potential efficacy of selpercatinib in treating intracranial metastases in RET fusion-positive patients with NSCLC after pralsetinib-refractory progression. The key takeaway is that selpercatinib may offer a viable treatment option in such scenarios, although more extensive studies are needed to determine its role as a monotherapy or in combination with other treatments.http://www.sciencedirect.com/science/article/pii/S2666364324001000RETSelpercatinibNon–small-cell lung carcinomaRET fusionNSCLCCase Report |
| spellingShingle | Illaa Smesseim, MD Tijmen van der Wel, MD Sushil K. Badrising, MD, PhD Intracranial Response to Selpercatinib After Pralsetinib-Induced Disease Progression in Rearranged During Transfection Fusion-Positive Non-Small-Cell Lung Cancer: Case Report JTO Clinical and Research Reports RET Selpercatinib Non–small-cell lung carcinoma RET fusion NSCLC Case Report |
| title | Intracranial Response to Selpercatinib After Pralsetinib-Induced Disease Progression in Rearranged During Transfection Fusion-Positive Non-Small-Cell Lung Cancer: Case Report |
| title_full | Intracranial Response to Selpercatinib After Pralsetinib-Induced Disease Progression in Rearranged During Transfection Fusion-Positive Non-Small-Cell Lung Cancer: Case Report |
| title_fullStr | Intracranial Response to Selpercatinib After Pralsetinib-Induced Disease Progression in Rearranged During Transfection Fusion-Positive Non-Small-Cell Lung Cancer: Case Report |
| title_full_unstemmed | Intracranial Response to Selpercatinib After Pralsetinib-Induced Disease Progression in Rearranged During Transfection Fusion-Positive Non-Small-Cell Lung Cancer: Case Report |
| title_short | Intracranial Response to Selpercatinib After Pralsetinib-Induced Disease Progression in Rearranged During Transfection Fusion-Positive Non-Small-Cell Lung Cancer: Case Report |
| title_sort | intracranial response to selpercatinib after pralsetinib induced disease progression in rearranged during transfection fusion positive non small cell lung cancer case report |
| topic | RET Selpercatinib Non–small-cell lung carcinoma RET fusion NSCLC Case Report |
| url | http://www.sciencedirect.com/science/article/pii/S2666364324001000 |
| work_keys_str_mv | AT illaasmesseimmd intracranialresponsetoselpercatinibafterpralsetinibinduceddiseaseprogressioninrearrangedduringtransfectionfusionpositivenonsmallcelllungcancercasereport AT tijmenvanderwelmd intracranialresponsetoselpercatinibafterpralsetinibinduceddiseaseprogressioninrearrangedduringtransfectionfusionpositivenonsmallcelllungcancercasereport AT sushilkbadrisingmdphd intracranialresponsetoselpercatinibafterpralsetinibinduceddiseaseprogressioninrearrangedduringtransfectionfusionpositivenonsmallcelllungcancercasereport |